Efficacy of Retinalamin in Patients with Retinitis Pigmentosa and Diabetic Retinopathy
Maximov I.B., Neroev V.V.
Helmholtz Moscow Research Institute of Eye Diseases
Introduction
Retinitis Pigmentosa (RP) is a genetic disorder leading to blindness. Diabetic Retinopathy (DR) is a vascular complication of diabetes. Both involve retinal cell death. Retinalamin is a peptide bioregulator isolated from the retina.
Methods
Patients with RP and DR received parabulbar injections of Retinalamin (5 mg) daily for 10 days. Visual acuity, visual fields, and electroretinography (ERG) were assessed before and after treatment.
Findings
Visual Fields
In RP patients, the progressive constriction of visual fields ("tunnel vision") was halted or significantly slowed in 70% of treated cases during the follow-up period.
Electrophysiological Activity
ERG recordings showed an increase in the amplitude of a- and b-waves, indicating improved functional activity of photoreceptors and bipolar cells.
Diabetic Retinopathy
In DR patients, Retinalamin reduced retinal edema and improved microcirculation, delaying the need for laser coagulation.
Conclusion
Retinalamin is a promising retinoprotective agent that can preserve vision in degenerative retinal diseases where few other treatments exist.
Key Findings
- ✓Stabilization of visual field loss in 70% of patients
- ✓Improved retinal electrical activity (ERG)
- ✓Reduction of retinal edema in diabetics
Mechanism of Action
Retinalamin stimulates the differentiation of retinal cells, improves retinal metabolism, and regulates vascular permeability in the eye.